miRecule is an early-stage biotechnology company developing microRNA-based therapeutics to address two of the major challenges in cancer therapy today. Two of the major problems in cancer therapy are accurately classifying patients based on how their unique cancer will respond to a given drug, and treating patients whose cancer initially responds to a drug, but then returns in a drug-resistant form. Our goal at miRecule is to create therapeutic drugs that address these two critical issues simultaneously, through a holistic drug development approach.